The FDA Just Wrote the Rulebook for Psychedelic Trials

What happened

In July 2026, the FDA finalized its guidance on how to run clinical trials for psychedelic drugs, replacing a draft it had published in June 2023.¹² FDA guidance isn't law, but companies that ignore it tend to regret it. This document is effectively the playbook every psilocybin, MDMA, and LSD developer will follow from here.

The blinding problem

In a normal drug trial, nobody knows who got the real pill. With psilocybin, most participants figure it out within an hour. That can inflate results, because people who know they got the drug expect to improve.

The FDA's guidance acknowledges this head-on and asks for results that are persuasive across multiple endpoints. It recommends alternatives to a plain placebo, such as a low dose of the psychedelic or another psychoactive comparison drug, plus independent raters who don't know which group a participant was in, and questionnaires that measure what participants expected and guessed.¹ Compass Pathways' trials already used a version of this, comparing 25 mg of psilocybin with a 1 mg dose.

Two people in the room

The guidance calls for two monitors during every dosing session. The lead needs graduate-level training and an independent license to practice psychotherapy. The assistant needs at least a year of licensed mental health experience. If the lead monitor isn't a physician, a licensed doctor must be on call and able to reach the site within 15 minutes.¹ That's a meaningful staffing requirement, and it shapes what an approved psilocybin treatment will cost.

Is it the drug or the therapy?

This is the most interesting part. The FDA says the contribution of psychotherapy to psychedelic treatment "has not been characterized," and suggests trial designs that can separate the drug's effect from the therapy's.¹ It's a pointed question after the agency declined to approve MDMA-assisted therapy in 2024, in part over concerns about how the trials were run.³

Compass has been building its case on this front, publishing an analysis showing that almost 80% of session time in one of its trials was spent in silence, with minimal, non-directive support.⁴

Proving it lasts

For chronic conditions like depression and PTSD, the FDA wants efficacy measured at 12 weeks in a double-blind design, followed by longer monitoring for relapse and the need for retreatment.¹ That matters because psilocybin's biggest selling point is durability.

Abuse potential testing

One piece of good news for developers: the guidance says certain animal studies of abuse potential typically aren't needed, and a dedicated human abuse study may be unnecessary if the drug's effects are already well characterized in clinical data.¹ That trims time and cost.

What it means for psilocybin

For Compass, which expects to complete its FDA application in Q4 2026, the final guidance mostly confirms the road it's already on. For everyone else, it's a clear set of expectations, and clearer rules usually mean faster, cheaper drug development. Read where things stand in the road to FDA approval.

Sources

1. Applied Clinical Trials. FDA finalizes guidance on clinical trial design for psychedelic drug development. July 15, 2026. appliedclinicaltrialsonline.com
2. Baker Donelson. FDA finalizes guidance on psychedelic drugs for clinical investigations. 2026. bakerdonelson.com
3. Pharmacy Times. FDA declines to approve MDMA for PTSD. August 2024. pharmacytimes.com
4. Compass Pathways. Second quarter and first half 2026 financial results and business highlights. August 5, 2026. seekingalpha.com

This article is for education only and is not medical or legal advice. Psilocybin is a Schedule I substance under U.S. federal law. Talk with a licensed clinician before making decisions about your health. In a crisis, call or text 988.